U.S. markets closed

Takeda Pharmaceutical Company Limited (TAK)

NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
15.39-0.56 (-3.51%)
At close: 4:00PM EDT
Sign in to post a message.
  • B
    Bassam
    Why is the share price dropping?
  • J
    Jay
    I plan on buying as many TAK shares as possible. Absolutely wonderful company that is positioned for significant growth.
  • H
    Haim
    ARK invest bought 144,000 more shares today
    Bullish
  • R
    Rod
    Got to admire the results of perfidy in the markets. FTM consensus earnings yield for FLXN is minus 17 percent and today's changing hands price range is 11.40 - 11.16. I'm thinking FLXN is an overvalued, overbought liability. FTM consensus earnings yield for TAK is positive 17 percent and today's price range is 17.90 - 17.77. I'm thinking TAK is an undervalued, underbought asset. All IMHO based on available info.
  • T
    Traves
    TAKE this ACOR to the bank or not?
  • 0
    0n0
    Anybody see that article about a supercomputer analysis on why certain COVID patients go down hill fast? It concluded that there was an over production of some molecule called bradykinin and some small sets of data backed that. The symptoms seem to fit very nicely too to the theory... Even more so than the cytokine storm theory. Currently there is a drug on the market called icatibant which blocks bradykinin... I looked up who makes it and it sells under the common brand name Firazyr.... Guess who makes this drug? Takeda! Here's to hoping this takes off!
  • D
    David
    I wish tak mgmt would allow the ADR dividend fee to be raised - 23% for fee and withholding taxes seems sooo low . . . . .
  • M
    Meatball
    This stock is booming when the broader market is roaring......(SARCASM). This was a long term investment but I may need to consider some sort of exit strategy once it recovers to $19. Sorry to be a Debbie downer here but I am frustrated with stock's performance for the past two years. For some reason wall street is not impressed with TAKEDA. Maybe it will shoot up as soon as I sell. Whoa is me.
    Neutral
  • B
    Bru
    Le site belge du groupe pharmaceutique japonais Takeda à Lessines a été sélectionné pour fournir des traitements à base de plasma sanguin dans le cadre d’une nouvelle étude clinique de phase 3 visant à prouver l’efficacité et la sécurité de ce type de thérapie.

    Si les essais cliniques s’avèrent positifs, ce site qui emploie actuellement 1.200 personnes fera plus que probablement partie de ceux qui produiront le médicament à grande échelle lors de la phase commerciale. « On nous a demandé d’être prêts et nous le serons. On est dans les starting-blocks, déclare au Soir Pierre Dorignaux, le patron de cette implantation.
  • M
    Meatball
    Up $0.48 today; down $0.63 tomorrow.
  • J
    Jim
    Sure could use new management here!!!!
  • H
    Haim
    ARK invest just bought 118,000 shares
    Bullish
  • G
    Georgios
    Do you think this stock can significantly go up when they start distributing the Novavax COVID-19 vaccine in Japan?
    Neutral
  • M
    Meatball
    Slapped back down as soon as it reaches $19. What a failure this stock is.
  • M
    Meatball
    I have about $80k tied to this stock.....It's like watching paint dry for the last 2 years. Every time it goes up a healthy $0.50-$1.00, it gives all the back the next couple of days. I guess we need a another major acquisition or a great partnership deal.
    Bullish
  • J
    Jay
    I'm truly grateful for the opportunity to buy at these prices. Five years from now.... you'll wish you owned more.
  • J
    Jim
    well it looks like the turd has come to life on the down side...hopefully it is just due to end of qtr selling and not something bad.
  • b
    blackoutbuzz
    A bit of pipeline news

    @@@Takeda Pharmaceutical- Phase 2 Elektra Study Of Soticlestat Meets Primary Endpoint
    Aug 25 (Reuters) - Takeda Pharmaceutical Co Ltd <4502.T>::PHASE 2 ELEKTRA STUDY OF SOTICLESTAT (TAK-935/OV935) MEETS PRIMARY ENDPOINT REDUCING SEIZURE FREQUENCY IN CHILDREN WITH DRAVET SYNDROME OR LENNOX-GASTAUT SYNDROME.TAKEDA PHARMACEUTICAL CO LTD - PRIMARY ENDPOINT ACHIEVED.TAKEDA PHARMA - STUDY SHOWS STATISTICALLY SIGNIFICANT REDUCTION IN SEIZURE FREQUENCY FROM BASELINE IN DRAVET SYNDROME COHORT COMPARED TO PLACEBO.TAKEDA PHARMACEUTICAL CO LTD - TAKEDA AND OVID PLAN TO INITIATE A PHASE 3 REGISTRATIONAL PROGRAM OF SOTICLESTAT IN DRAVET SYNDROME.TAKEDA PHARMA - SOTICLESTAT WELL-TOLERATED, DEMONSTRATED SAFETY PROFILE CONSISTENT WITH FINDINGS OF PREVIOUS STUDIES WITH NO NEW SAFETY SIGNALS IDENTIFIED.
  • l
    lilsawmus
    Any thoughts on when Takeda and Novavax will have have NVX-CoV-2373 approved and out to market in Japan? Novavax appears to have the most efficacious vaccine to date and it's safe. This seems like a major win win for both companies.
    Bullish
  • J
    Johnny
    The FDA today approved the use of Convalescent Plasma as a treatment for Covid 19. According to the FDA it will save 35% more lives.